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Background: Sar1 mediates the onward transport of ER cargo.
Results: Sar1B promotes VLDL secretion, whereas Sar1A antagonizes this activity, and a deficit of both reduces cholesterol
biosynthesis.
Conclusion: Sar1B independently of and through its lipoprotein secretion function promotes the expression of genes regulating
cholesterol biosynthesis.
Significance: Sar1B-mediated transport activities contribute to both the functional integrity of the ER membrane and blood
cholesterol levels.
Triglycerides and cholesterol are essential for life in most
organisms. Triglycerides serve as the principal energy storage
depot and, where vascular systems exist, as a means of energy
transport. Cholesterol is essential for the functional integrity of
all cellular membrane systems. The endoplasmic reticulum is
the site of secretory lipoprotein production and de novo choles-
terol synthesis, yet little is known about how these activities are
coordinated with each other or with the activity of the COPII
machinery, which transports endoplasmic reticulum cargo to
theGolgi. The Sar1B component of thismachinery ismutated in
chylomicron retention disorder, indicating that this Sar1 iso-
form secures delivery of dietary lipids into the circulation. How-
ever, it is not knownwhy some patients with chylomicron reten-
tion disorder develop hepatic steatosis, despite impaired
intestinal fat malabsorption, and why very severe hypocholes-
terolemia develops in this condition. Here, we show that Sar1B
also promotes hepatic apolipoprotein (apo) B lipoprotein secre-
tion and that this promoting activity is coordinated with the
processes regulating apoB expression and the transfer of triglyc-
erides/cholesterol moieties onto this large lipid transport pro-
tein.Wealso show that althoughSar1Aantagonizes the lipopro-
tein secretion-promoting activity of Sar1B, both isoforms
modulate the expression of genes encoding cholesterol biosyn-
thetic enzymes and the synthesis of cholesterol de novo. These
results not only establish that Sar1B promotes the secretion of
hepatic lipids but also adds regulation of cholesterol synthesis to
Sar1B’s repertoire of transport functions.
Whole-body triglyceride and cholesterol homeostasis are of
fundamental importance to human health. Their failure mani-
fests in multiple diseases, ranging from life-threatening condi-
tions in infancy (1–4), to severe coronary heart disease in young
adults (5, 6), and to indolent disorders of middle and old age
(7–11). In higher organisms, the ability of tissues to accommo-
date large fluctuations in dietary triglyceride and cholesterol
intake is well developed, involving cross-talk between the cel-
lular processes that govern the delivery of these lipids into the
circulation via triglyceride-rich, apoB-containing lipoproteins,
their uptake, de novo lipogenesis, and cholesterol biosynthesis
(12). From the study of familial hypobetalipoproteinemia
(OMIM107730) and abetalipoproteinemia (OMIM 200100),
it is evident that both apolipoprotein (apo)B and the micro-
somal triglyceride transfer protein (MTTP)4 are obligatory for
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the production of chylomicrons and very low density lipopro-
teins (VLDL) within the endoplasmic reticulum (ER) of entero-
cytes and hepatocytes, respectively (1, 13–15). Moreover,
human liver, in contrast to the intestine, uses apoB100 rather
than the shorter apoB48 for exporting lipid into the circulation
(12). Sar1B, a coat protein II (COPII) component, has also been
shown to be central to the lipid economy by the discovery that
its mutations cause the rare recessive disorder chylomicron
retention disease (CMRD) (OMIM 246700) (2). However, it is
not clear why this GTPase is obligatory for delivery of chylomi-
crons into the circulation and whether this relates to the usage
of apoB48 rather than apoB100 for their production or insuffi-
cient Sar1A in the intestine of CMRD patients to compensate
for loss of Sar1B function.
It is also not known why some CMRD children develop
hepatic steatosis (16–18), despite severe intestinal fat malab-
sorption; and it is very odd that affected individuals develop
severe hypocholesterolemia (2, 16–18), because therapeutic
reduction of intestinal cholesterol absorption only modestly
affects circulating cholesterol levels, due to compensatory rises
in endogenous de novo cholesterol biosynthesis (12, 19, 20).
Indeed,Western-type diets provide400mg of cholesterol per
day, and our bodies synthesize 1 g de novo (21, 22). Hence,
blood cholesterol levels reflect both dietary and endogenously
synthesized cholesterol.
Cholesterol synthesis is a multistep reaction that is thought
to occur in virtually all nucleated cells (23). In this context, it
may be relevant that SAR1B expression has been detected in
multiple tissues (2); most of the enzymes synthesizing choles-
terol de novo reside in the ER membrane (24–28), including
HMG-CoA reductase (29), the target of statins, a highly suc-
cessful class of cholesterol-lowering drugs (30, 31). Hepatic bio-
synthesis may be especially sensitive to intestinal cholesterol
absorption because of the liver’s central position in directing
cholesterol into VLDL or bile (32). After uptake by enterocytes,
cholesterol is packed with triglycerides into chylomicrons and
secreted into the lymph. In the circulation, the triglycerides are
rapidly hydrolyzed, and the released glycerol and fatty acids
taken up by peripheral tissues, whereas the cholesterol-en-
riched, highly atherogenic remnant particles are captured by
the liver (33, 34). From internal cellular endosomal compart-
ments, the cholesterol may be returned to the plasma mem-
brane (35) or be transported to the ER (36, 37).
In ER membranes, cholesterol may suppress the activities of
one or more cholesterol biosynthetic enzymes or activate acyl-
CoA:cholesterol acyltransferase (ACAT) 2 (38–41). It may also
impede binding between the COPII protein Sec24 and the ste-
rol regulatory element-binding protein (SREBP) escort protein
Scap (42, 43), thereby blocking export of the ER membrane-
bound Scap-SREBP2 complex to the Golgi apparatus (44).
Here, SREBP2 undergoes proteolytic cleavage, culminating in
the release of its amino-terminal domain (45), known to tran-
scriptionally activate genes regulating cholesterol homeostasis
(46–50). However, it is not known whether the Sar1B compo-
nent of the COPII transport machinery contributes to the ER
export of SREBP2, de novo cholesterol synthesis, or the secre-
tion of cholesteryl esters via VLDL.
Studies with Sar1 bound to nonhydrolysable analogues of
GTP and a GTP-restricted form of Sar1 (i.e. Sar1:H79G) have
defined several aspects of the COPII vesicle assembly process
(51–54). In outline, Sar1-GDP is recruited to the cytosolic face
of the ER membrane. Here, the guanine-nucleotide exchange
protein Sec12 swaps the GDP on Sar1 for GTP. Next, the Sar1-
GTP recruits Sec23/24 to the ER membrane to form a pre-
budding complex that captures both ER cargo and Sec13/31
(55, 56), culminating in polymerization of the COPII coat and
fission of the COPII vesicle from the ER, alongwith its captured
cargo. This process, including the sorting of ER cargo into
COPII pre-budding complexes, is coupled to the hydrolysis of
Sar1’s GTP; Sec12 continually reactivates Sar1, promoting con-
tinued pre-budding complex assembly and cargo capture,
whereas unchecked GTP hydrolysis triggers coat disassembly
(52–55).
In CMRD, most SAR1B mutations alter an amino acid in
Sar1B’s GDP/GTP binding pocket (2, 17, 18), suggesting that
the intestinal fat malabsorption defect is attributable to break-
down/absence of the Sar1 GTPase cycle that normally secures
capture of nascent chylomicrons into COPII pre-budding com-
plexes and their subsequent onward transport. However, it is
not known whether this breakdown relates to a specific
aspect(s) of the apoB lipoprotein/COPII vesicle working rela-
tionship, and it is unclear to what extent Sar1B’s homologue
Sar1A can compensate for loss of Sar1B in this partnership.
Additionally, there are no data regarding the contributions of
the Sar1A- and Sar1B-GTPase cycles in securing VLDL secre-
tion and cholesterol homeostasis.
Here, we demonstrate that ubiquitously expressed Sar1B (2)
acts at two control points crucial to cholesterol metabolism.
First, Sar1B promotes hepatic apoB100-lipoprotein secretion
(aswell as apoB48-lipoprotein secretion), and this is pairedwith
expression changes in APOB and MTTP, but not of genes
involved in triglyceride synthesis. The apoB lipoprotein secret-
ing activity of Sar1B is antagonized by Sar1A. This is more pro-
nounced for themore triglyceride-rich apoB lipoproteins, indi-
cating that only Sar1B has the attributes to mediate the
assembly of COPII pre-budding complexes of the right struc-
tures and composition to secure export of such nascent apoB
lipoproteins and hence efficient delivery of triglyceride and
cholesterol moieties into the circulation. Second, deficiency of
Sar1B, but not Sar1A, in apoB lipoprotein-producing cells
reduces ER export of Srebp2, whereas aggregate levels of Sar1
determine the rate of de novo cholesterol synthesis. The study
indicates that Sar1B, both independently of and through its
promotion of apoB-mediated lipid secretion activities, contrib-
utes to the regulation of cellular, as well as plasma, triglyceride
and cholesterol levels.
EXPERIMENTAL PROCEDURES
Production of Stable Cell Lines, Knockdown, and Tissue
Culture—Human SAR1A and SAR1B sequences were PCR-am-
plified from Marathon-ready human liver cDNA (Clontech)
using gene-specific primers. FLAG epitope tags (Asp-Tyr-Lys-
Asp4-Lys) were fused in-frame to the carboxyl termini of
cDNAs and juxtaposed to a terminator codon. PCR and appro-
priate restriction sites were used to manipulate the SAR1
Sar1B-mediated Regulation of Triglyceride and Cholesterol
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sequences. Site-directed mutagenesis was performed by a
standard two-step PCR-based strategy (57). All constructs were
sequenced before use. Transfection of pcDNA4/TO vectors
intoMcArdle-RH7777 (58) andCHO (Invitrogen) cell lines sta-
bly transformed with pcDNA6/TR was performed with either
FuGENE (Roche Applied Science) or Lipofectamine Plus Rea-
gent (Invitrogen). Individual cloneswere picked, expanded, and
screened for recombinant protein expression using serial dilu-
tions of cell lysates, anti-FLAGM2 antibody (Sigma-Aldrich), a
goat anti-mouse IgG horseradish peroxidase-conjugated sec-
ondary antibody (Bio-Rad), and Femto-enhanced chemilumi-
nescence (Pierce). Blots were scanned on a flatbed scanner and
immunoreactive products quantified using Adobe Photoshop.
Cell lines (two per construct) were selected to have comparable
levels of recombinant protein expression.
Knockdowns were performed with pre-designed siRNA
(Qiagen) usingHiPerFect transfection reagent (Qiagen) according
to the manufacturer’s fast forward protocol. Volumes of trans-
fection reagents and concentrations of siRNA were optimized
for each pre-designed FlexiTube siRNA (Qiagen). The best
results were obtained using a final concentration of 5 nM
siRNA. For the double-knockdown experiments, 5 nM of each
isoform was used. The scrambled siRNA sequence was 5-
UUCUCCGAACGUGUCACGUdTdT-3 (Qiagen).
McArdle-RH7777 cells were cultured at 37 °C, 5% CO2 in
DMEMcontaining 20%heat-inactivated FCS (Labtech Interna-
tional), 4500 mg/liter D-glucose, 2 mM L-glutamine (Invitro-
gen), and 1% penicillin/streptomycin (Invitrogen). CHO cell
lines were cultured in Ham’s F-12 media (Sigma) containing
10%heat-inactivated FCS, 2mML-glutamine, and 1%penicillin/
streptomycin. Blasticidin (10 g/ml; Sigma) and Zeocin (250
g/ml; Invitrogen) were added to the media of cells stably
transfected with the tetracycline repressor (pcDNA6/TR) and
operon (pcDNA4/TO) vectors (Invitrogen).
Metabolic Labeling, Immunoprecipitations, and SucroseGra-
dient Ultracentrifugation of ApoB Lipoproteins—Prior to label-
ing for 1 h with 125 Ci/ml L-[35S]methionine (ICN Flow) at
37 °C, cells were incubated with complete DMEM containing 1
g/ml tetracycline between 24 and 48 h and then in serum-free
media supplementedwith 0.8mMoleic acid (Sigma) complexed
to 3% fatty acid-free BSA overnight and cysteine/methionine-
free media (Invitrogen) containing oleate for 30 min. After
removal of label, incubations were continued in serum-free
media supplemented with 0.8 mM oleic acid complexed to 3%
fatty acid-free BSA for 2 h. Conditioned media were cleared by
low speed centrifugation and concentrated to 500l in Amicon
Ultra-4 centrifugal filter units with Ultracel-30 membranes
(Millipore). ApoB was immunoprecipitated by standard meth-
odology (59, 60), using saturating concentrations of goat poly-
clonal antibody against human apoB (AB742; Chemicon Inter-
national), as described (13, 59, 60). The radioactivity in apoB48
and apo100 was quantified by phosphorimager analysis. Three
samples were collected per stable cell line per experiment.
For total protein secretion measurements, cells were incu-
bated in methionine-free medium for 45 min at 37 °C and
labeled for 1 h with 125 Ci/ml L-[35S]methionine (ICN Flow).
After removal of label, incubations were continued in serum-
free medium for 2 h. Cell media were harvested, mixed with
protease inhibitors (Calbiochem), and cleared by low speed
centrifugation. Proteins were precipitated by incubation with
TCA for 15 min on ice. Precipitates were washed in ice-cold
acetone and resuspended in I.P. buffer containing protease
inhibitors (Calbiochem).
Densities of secreted 35S-labeled apoB lipoproteins were
determined by gradient ultracentrifugation. The sucrose gradi-
ents were formed as described (13), except that the gradients
were ultracentrifuged at 35,400 rpm in a Beckman SW41 rotor
and unloaded in 12 fractions. ApoB was recovered from each
fraction by immunoprecipitation and size-fractionated by SDS-
PAGE, and the amount of radioactivity in apoB48 and full-
length apoB100 was quantified by phosphorimager analysis.
The density profile of the gradient was determined using an
Abbe refractometer.
Immunoblot Analysis of Endogenous Protein Expression—
Cell lysates were generated using RIPA buffer (Sigma) and a
mixture of protease inhibitors (Roche Applied Science). Pro-
teins were size-fractionated on either 10 or 4–12% gradient
NuPage BisTris precast gels (Invitrogen) and transferred to
nitrocellulosemembranes (Whatman).Membranes were blocked
in 5% (w/v) nonfat milk powder before probing with the speci-
fied antibodies. The antibodies used were as follows: rabbit
polyclonal anti-Hmgcs1 antibody (Proteintech); anti-Lss anti-
body (Proteintech); anti-Dhcr7 antibody (Abcam); anti-ACSL5
(Proteintech); anti-Sec13 antibody (Abcam); anti-Sec31a anti-
body, anti-Sar1a antibody, anti-Sar1b antibody, and anti-Srebf2
antibody (Proteintech); anti-ATF6 (Abcam); andmousemono-
clonal -actin or -tubulin antibodies (Sigma and Abcam).
Immunoreactive products were visualized and quantified after
labeling with appropriate fluorescent dye-labeled secondary
antibodies (LI-COR Biosciences) using the Odyssey imaging
system (LI-COR). Apparent molecular masses were esti-
mated using the Novex Sharp Protein Standard (Invitrogen)
and the band sizing application in Odyssey software (LI-
COR Biosciences).
RT-qPCR Analyses in Cell Lines—Pre-designed gene primers
were purchased from Qiagen (Quantitect primer assay), unless
stated otherwise (supplemental Table S1). Total RNA was iso-
lated from cell lysates using the RNeasyPlus kit (Qiagen). Cells
were homogenized using QIAshredder columns (Qiagen).
RNA samples were quantified by a NanoDrop 1000 spectro-
photometer (Thermo Scientific). RT-qPCRswere performed in
triplicate (with a no RT control) with SYBR Green kits from
Qiagen or Stratagene, as recommended by the manufacturers.
Data were analyzed with either SDS 2.3 software (Applied Bio-
systems) or MxPro (Stratagene). Gene expression levels, nor-
malized to Ppia, were calculated by the relative 2Ctmethod
(61).
RNA Analyses of Human Small Intestine Biopsies and Liver
Samples—After an overnight fast, gastroduodenoscopy was
performed, and small intestinal (jejunal) biopsies were taken
near the Treitz’ ligament in 17 obese male subjects with no
history of disease or any medication use (i.e. treatment-naive).
To minimize variability in sample processing and handling,
biopsy samples were collected immediately and snap-frozen in
liquid nitrogen. All subsequent sample processing was per-
formed by the same individual using the same standardized
Sar1B-mediated Regulation of Triglyceride and Cholesterol
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protocol. Tissue was homogenized in MagNA Pure LC RNA
Isolation Tissue Lysis Buffer (Roche Applied Science), using a
MagNALyser instrument (Roche Applied Science), and using
parameters that were optimized on comparable samples prior
to commencing the study. Total RNA was prepared using
TRIzol according to the manufacturer’s manual (Invitrogen),
quantified by a NanoDrop 1000 spectrophotometer (Thermo
Scientific), and reverse-transcribed into cDNA using a cDNA
synthesis kit from Bio-Rad. RT-qPCR was performed in tripli-
cate with 50 ng of cDNA, 200 nM of each primer, and 7.5 l of
SYBRGreenmix (CE Biotech). PCRs were performed on a CFX
system (Bio-Rad). Gene expression levels normalized to 36B4
were calculated by the relative 2Ct method (61). The study
was approved by the Research EthicsCommittee atAmsterdam
Medical Center, Amsterdam, The Netherlands, and all partici-
pants gave written informed consent.
RT-qPCR on human liver RNA (First Choice Human Total
RNA, Applied Biosytems) was performed with a SYBR Green
kit (Qiagen). Correlations betweenmRNA levels in human liver
samples (62, 63) were computed using R2, a Genomics Analysis
Visualization Platform. p values were corrected for multiple
testing using the formula implemented in R2: t  R/sqrt(1 
Rˆ2)/(n  2), where R is the correlation coefficient, and n
denotes the number of samples.
Microarray Gene Analyses—A minimum of three technical
replicates were used for each of two Sar1B:H79G-FLAG cell
lines, two control cell lines, two Sar1B-FLAG cell lines, and one
Sar1A-FLAG cell line. Cells were cultured in complete DMEM
containing blasticidin (10 g/ml; Sigma) and Zeocin (250
g/ml; Invitrogen). Twenty four hours prior to harvesting, 1
g/ml tetracycline was added to the culture media. Total RNA
was extracted with the RNeasy Plus mini kit (Qiagen). RNA
quality was verified (e.g. flat baseline between 18 S and 28 S
ribosomal RNA peaks; RIN score7) using the RNA 6000 Lad-
der (Ambion), RNA 6000 NanoChip (Agilent), plus an Agilent
2100 bioanalyzer (Agilent Technologies, Germany). cDNAwas
synthesized from total RNA using the one-cycle eukaryotic tar-
get labeling assay kit (Invitrogen and Affymetrix). Double-
stranded cDNA was purified with the GeneChip sample
cleanup module. Biotin-labeled cRNA was prepared using the
BioArray High Yield RNA transcript labeling kit (Enzo) and
purified with the in vitro transcription cRNA GeneChip sam-
ple cleanup module. RNA quality was verified with the Agilent
Bioanalyzer 2100 system and by hybridization to test arrays
(Affymetrix). Biotinylated cRNA (20 g) was hybridized to
GeneChip rat genome 230 2.0 arrays (Affymetrix) containing
31,099 probe sets. All cRNA samples were prepared using the
same standard protocol.
Data analyses were performed through the CARMAweb
(Comprehensive R-based Microarray Analysis web service).
Raw intensity values were normalized using the Loess normal-
ization, AffymetrixMAS 5 and summarization algorithms. Dif-
ferences in probe-set values were determined on the normal-
ized data using the significance analysis of microarray (SAM)
algorithm (64) at specified false discovery rates (FDR). These
were determined using the “Benjamini and Hochberg” correc-
tion, with cutoff values for significance determined by a tuning
parameter, the “ value.” The number of values was set at 50.
Data are available at NCBI Gene Expression Omnibus (GEO
accession number GSE52969). The differentially expressed
probe sets were examined for enrichment of functionally
related Gene Ontology terms using the Database for Annota-
tion, Visualization, and Integrated Discovery (DAVID; david.
abcc.ncifcrf.gov) (65, 66).
Lipid Synthesis and Secretion—Cells were seeded at a density
of 1 	 104 cells/cm2 in 9-cm plates and grown for 2 days in
DMEM containing 20% FCS, 1% penicillin/streptomycin, and 1
mM glutamine at 37 °C under 5% CO2. Lipid synthesis was
measured over the final 5 h of the incubation by the addition of
2mM [14C]acetate (sodiumsalt; Sigma) (0.8Ci/ml). Cellmedia
were aspirated for analysis of lipid secretion. Cells were washed
in PBS and harvested by trypsinization and centrifugation. Cell
pellets were washed in PBS and lipids extracted by addition of 4
ml of chloroform/methanol (2:1).Water (1ml)was added to the
extract and mixed by vortexing. The suspension was centri-
fuged for 5 min, and the lower solvent layer was taken for anal-
ysis. The upper aqueous layer was re-extracted with a further 4
ml of chloroform/methanol, and the two extractionswere com-
bined. This was dried down under N2 and resuspended in a
minimal volume of hexane (30 l). Cell medium (4 ml) was
extracted as above, using 16 ml of chloroform/methanol (2:1).
Lipids were separated by thin layer chromatography on Silica
Gel 60 plates (VWR) using petroleum ether/diethyl ether/ace-
tic acid (60:40:1) as the mobile phase and visualized by iodine
staining. Each run included standards of cholesterol, fatty acids,
triglycerides and cholesterol esters. Lipid synthesis was mea-
sured by scraping of spots into vials followed by liquid scintil-
lation counting. Plates were also visualized by autoradiography
to determine that no major lipid product was missed.
Statistics—All data are expressed as means
 S.E. Statistical
analyses were performed using unpaired Student’s t test or one-
way analysis of variance followed by the Bonferroni post hoc
test using PASW Statistics version 18.0 software (SPSS, IBM),
where appropriate. Figures were generated using Graphpad
Prism 4.
RESULTS
Characterization of the Effects of Sar1 Isoforms onApoB Lipo-
protein Secretion—To establish whether Sar1B promotes only
the secretion of apoB48-containing lipoproteins, we stably
transfected McArdle-RH7777 cells that can secrete both
apoB48 and apoB100 lipoproteins with constructs encoding
Sar1A-FLAG, Sar1B-FLAG, or constitutively active Sar1-FLAG
(i.e. Sar1A:H79G and Sar1B:H79G) isoforms that cannot
hydrolyze GTP to support completion of COPII vesicle assem-
bly (67). Despite several attempts, we failed to stably transfect
McArdle-RH7777 cells with Sar1A:H79G, potentially because
Sar1a mRNA is the predominant species expressed in these
cells (11.6-fold higher than Sar1b). The Sar1A cell lines con-
tained 5.26 
 0.48- and 2.41 
 0.48-fold, respectively, more
recombinant Sar1 than the Sar1B and Sar1B:H79G cell lines.
Sar1B:H79Goverexpression virtually abolished the secretion
of both apoB48 and apoB100 lipoproteins (Fig. 1A). By contrast,
Sar1B overexpression increased their secretion by3-fold (Fig.
1B). Their densities were not decreased (Fig. 1, C and D) with
both the apoB48- and apoB100-containing lipoproteins exhib-
Sar1B-mediated Regulation of Triglyceride and Cholesterol
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iting their expected densities (13). Sar1A overexpressionmark-
edly reduced apoB lipoprotein secretion (Fig. 1E); however, the
effect was more pronounced for apoB100 than apoB48 (secre-
tion 3.49 
 1.5% (apoB100) and 20.65 
 3.97% (apoB48) of
control cells, respectively; p 0.0016 for difference). Total pro-
tein secretion was also decreased in the Sar1B:H79G cell lines
(Fig. 1F), but this reduction was significantly less than that
observed for apoB48/100 (Fig. 1A). Collectively, these data
show that Sar1B promotes secretion of both apoB48 and
apoB100 lipoproteins, whereas Sar1A overexpression has the
opposite effect, preferentially blocking the secretion of the
more lipid-laden particles.
To determine whether Sar1 also had isoform-specific effects
on the expression of ApoB andMttp, we measured the levels of
their RNAs byRT-qPCR in ourMcArdle-RH7777 cell lines plus
McArdle-RH7777 cells transfected with Sar1 siRNAs. Individ-
ual knockdown of the Sar1 isoforms were isoform-specific, and
there were no increases in the mRNA (Fig. 2A) or protein (Fig.
2B) levels of the nontargeted isoform. The amounts of Sar1a
protein in cells transfected with Sar1a and Sar1a plus Sar1b
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FIGURE 1. Sar1A and Sar1B have opposite effects on apoB48- and apoB100-containing lipoprotein secretion. A and B, McArdle-RH7777 cells were
labeled with L-[35S]methionine for 60 min and chased for 120 min. The L-35S-labeled apoB in the cell media was immunoprecipitated, analyzed by SDS-PAGE,
andvisualizedbyphosphorimaging.Data (mean
 S.E.) are from four independent experiments.****,p0.0001 versus cellswith empty vector control. ***,p
0.001 versus cells with empty vector control. **, p 0.01 versus cells with empty vector control. C andD,densities of fractions containing secreted L-35S-labeled
apoB48-containing (C) and L-35S-labeled apoB100-containing (D) lipoproteins were determined gravimetrically. Data (mean
 S.E.) are from three indepen-
dent experiments. E, secreted L-35S-labeled apoB from two independent Sar1A-FLAG cell lines, quantified as inA and B. ****, p 0.0001 versus cells with empty
vector control. **, p 0.01 versus apoB100 lipoproteins. F, total L-[35S]methionine in secreted protein fraction. Data (mean
 S.E.) are from five independent
experiments. ****, p 0.0001 versus cells with empty vector control.
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siRNAs were 28.16 
 6.36 and 32.88 
 8.70%, respectively, of
that in cells transfected with the scrambled siRNA control (Fig.
2B). Sar1b knockdown also substantially reduced in Sar1b
protein and in the majority of samples to undetectable levels
(Fig. 2B). This was due to theWestern blot analysis returning
weaker signals for Sar1b than Sar1a, consistent with
RT-qPCR data (Sar1b mRNA 11.6-fold lower than Sar1a
mRNA), plus the efficiency of Sar1b knockdown in reducing
Sar1b protein (70% in the rare knockdown sample where it
could be quantified).
Although constitutively active Sar1B increased Sar1amRNA
(4.22
 0.29-fold comparedwith control cells) and protein (Fig.
2C), it reduced ApoB and Mttp mRNA (Fig. 2D). Levels of the
control gene,Mapk1,were not altered (Fig. 2D). In the comple-
mentary analyses, native Sar1B overexpression increased ApoB
mRNA (Fig. 2D), while having no effect onMttp (Fig. 2D) and
Sar1a (1.27 
 0.03-fold, nonsignificant) mRNAs; and Sar1b
knockdown reduced ApoB and Mttp mRNA (Fig. 2E) and had
no significant effect on Sar1a mRNA (Fig. 2A). In the control
analysis, ApoB and Mttp knockdown (Fig. 2F) did not reduce
Sar1b mRNA (Fig. 2G). Interestingly, we found that Sar1A
overexpression decreased Mttp mRNA levels, although Sar1a
knockdowndid not increaseMttpmRNA (Fig. 2E). However, in
the double knockdown experiment, decreased Sar1a did pre-
vent the fall in Mttp (and apoB) associated with Sar1b knock-
down (Fig. 2E). Thus, collectively these data indicate that Sar1
has isoform-specific effects on ApoB and Mttp mRNA levels.
Moreover, because a higher level of MTTP activity is required
for producing apoB100 than apoB48 lipoproteins (15), the
observed changes in ApoB andMttp expression may form part
of the adaptive responses to Sar1-induced changes in apoB lipo-
protein secretion.
FIGURE 2. Effect of constitutively active Sar1B and native Sar1 expression on ApoB andMttp expression in McArdle-RH7777 cells. A and B, isoform-
specific effects of Sar1a and Sar1b knockdownon transcript (A) and protein (B) analyzed by RT-qPCR and quantitativeWestern blot analysis.NQ, not quantified
due to undetectable levels of Sar1b in some cell lysates. White line separators indicate that noncontiguous lanes from the same gel are shown. A, *, p 0.05
versus Sar1a  Sar1b knockdown. B, ***, p  0.001 versus scrambled control siRNA; **, p  0.01 versus scrambled control siRNA. C, Sar1a protein in stably
overexpressing Sar1B:H79G and empty vector control cells. *, p 0.05 versus cells with empty vector control.D, Sar1 isoform-specific effects on ApoB andMttp
mRNA levels in overexpressing cell lines, analyzed by RT-qPCR. ***, p 0.001 versus cells with empty vector control. E, Sar1b knockdown specifically reduces
ApoB andMttpmRNA, analyzed by RT-qPCR. **, p 0.01 versus scrambled control siRNA. F and G, ApoB andMttp knockdown (F) does not decrease Sar1a and
Sar1bmRNA (G), analyzed by RT-qPCR. A–G, data (mean
 S.E.) are from at least three independent experiments.
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Because clinical studies have indicated that SAR1B muta-
tions affect chylomicron secretion and, despite intestinal fat
malabsorption, some children with CMRD develop fatty liver
(2, 16–18), we examined relative SAR1A and SAR1B mRNA
levels in human intestinal biopsies and liver samples. In addi-
tion, we examined the correlation between SAR1, APOB, and
MTTPmRNA in publically available human liver gene expres-
sion datasets.
We found that SAR1B mRNA levels were 239 
 84- and
3-fold, respectively, higher than SAR1A in intestinal mucosal
biopsies (17 donors) and a pooled (three donors) liver sample.
By contrast, the predominant SEC23 (A) and SEC31 (A) iso-
forms expressed in these two tissues displayed more compara-
ble mean fold differences; in the intestinal biopsies, SEC23A
and SEC31Awere 5.0
 0.9- and 43
 12-fold higher than their
respective B isoforms; and in the pooled liver sample, the cor-
responding values were 3.2 and 29.4.
We also found positive correlations between hepatic SAR1B,
but not SAR1A, mRNA levels and APOB/MTTPmRNA. Thus,
in a large dataset comprising 427 individual liver samples, the
correlation coefficient (R) between SAR1B and APOB mRNA
was 0.301 (p 8.3	 109), and in the second dataset, compris-
ing 75 samples, this result was replicated (R 0.292, p 0.01).
Likewise, R values between SAR1B and MTTP mRNA were
0.268 (p 2.5	 108) in dataset 1 and 0.346 (p 2.4	 103)
in dataset 2. SAR1A displayed no positive correlation with
either APOB or MTTP mRNA levels; R values for the SAR1A/
APOB correlations were 0.003 (dataset 1, p NS) and0.012
(dataset 2, p  NS) and between SAR1A and MTTP, 0.179
(p  2.3 	 104) and 0.019 (p  NS). Notably, the weak
inverse correlation between SAR1A andMTTPmRNA levels in
dataset 1 is consistent with the effect of Sar1A overexpression
onMttpmRNA levels in McArdle-RH7777 cells (Fig. 2D), plus
theMttpmRNA findings in the set of Sar1 knockdown exper-
iments (Fig. 2E).
Thus, collectively our results (e.g. Fig. 2, D and E) and the
previous characterization of the COPII vesicle assembly pro-
cess (51, 54, 56, 68) are consistent with a model whereby the
expression of APOB andMTTP, which are obligatory for apoB
lipoprotein production in the ER lumen (12, 69, 70), are mod-
ulated by the expression of Sar1B,which facilitates the export of
nascent apoB lipoproteins (and potentially other associated
cargo) out of the ER in COPII-coated vesicles.
Characterizing Sar1 Effects on Gene Expression and de Novo
Cholesterol Biosynthesis—In view of the lipid transport func-
tions of apoB, we determined whether constitutively active
Sar1B altered the expression of genes regulating triglyceride,
fatty acid, and cholesterol homeostasis. To this end, we per-
formed a microarray RNA analysis on the McArdle-RH7777
cell lines and validated the robustness of the results by mea-
suring SecmRNA levels via RT-qPCR in an independent exper-
iment (supplemental Table S2). In addition, we confirmed that
the respective 2.73 
 0.15- and 2.90 
 0.47-fold increases in
Sec13 and Sec31amRNA associated with Sar1B:H79G overex-
pression (supplemental Table S2) were congruent with esti-
mated rises in Sec13 (1.7
 0.20-fold) and Sec31a (4.72
 0.94-
fold) protein.
We identified 701 probe sets that had altered expression val-
ues (FDR 0.000215) in the Sar1B:H79G cell lines only (Fig.
3A). In the control analyses (i.e. native Sar1 overexpression),
fewer probe sets were uniquely differentially expressed as fol-
lows: three in the Sar1A- and 70 in the Sar1B-overexpressing
cell lines (supplemental Fig. S1). The Sar1B:H79G probe set
contained an over-representation of genes assigned the Gene
Ontology terms “Cholesterol and Lipid Biosynthetic and Met-
abolic Processes” (Table 1), although neither the Sar1A nor
Sar1B datasets did (supplemental Tables S3 and S4). We there-
fore collated the expression values for genes active in fatty acid,
triglyceride, and cholesterol metabolism, and verified the
mRNA levels of representative genes in an independent exper-
iment by RT-qPCR (supplemental Table S5).
Despite reduced secretion of apoB lipoproteins from the
Sar1B:H79Gand Sar1A cell lines (Fig. 1,A andE), and increased
apoB-secretion from Sar1B cells (Fig. 1B), we found that the
levels of most transcripts encoding proteins active in fatty acid
and triglyceride metabolism were unaltered by increases in
Sar1A expression in the Sar1A and Sar1B:H79G (Fig. 2C) cell
lines and by Sar1B overexpression (supplemental Table S5). By
contrast, constitutively active Sar1B decreased the levels of
most mRNAs encoding enzymes on the cholesterol biosyn-
thetic pathway (Fig. 3B and supplemental Table S5), whereas
overexpression of native Sar1A and -B did not (supplemental
Table S5).
Western blot analysis of Sar1B:H79G cell lysates revealed
markedly reduced levels ofHmgcs1 and Lss protein (Fig. 3C, 1st
and 2nd panels), whereas Dhcr7, which converts 7-dehydro-
cholesterol to cholesterol and 7-dehydrodesmostrel to 24-de-
hydrocholesterol (Fig. 3B), was increased2-fold (Fig. 3C, 3rd
panel). In a control analysis, Sar1B:H79G did not alter RNA
(supplemental Table S5) or protein levels of Acsl5 (Fig. 3C, 4th
panel), a key regulator of fatty acid metabolism (71). Further-
more, Sar1A overexpression, which also markedly impaired
apoB lipoprotein secretion (Fig. 1E), did not reduce Hmgcs1
and Lss protein (Fig. 3D) or increase Dhcr7 protein (Fig. 3D).
Rather Hmgcs1 protein was increased (Fig. 3D, 1st panel).
Sar1B overexpression had a variable impact on Hmgcs1 pro-
tein levels and only significantly reduced Lss (Fig. 3D). How-
ever, no increase in Dhcr7 protein was observed, and inmarked
contrast to Sar1A and Sar1B:H79G overexpression, Ascl5 pro-
tein was reduced (Fig. 3D). Thus, these data indicate that over-
expression of Sar1A, Sar1B, and Sar1B:H79G have distinct
effects on Hmgcs1, Dhcr7, and Acsl5 protein levels and that
only Sar1B:H79G significantly reduced levels of mRNA encod-
ing cholesterol-biosynthetic enzymes (supplemental Table S5).
In a further control experiment, we found that knockdown of
ApoB and Mttp did not significantly reduce mRNA levels of
cholesterol pathway-encoding enzymes (supplemental Fig. S2).
Thus, these data substantiate the evidence from the Sar1A gene
expression (supplemental Table S5) and apoB secretion results
(Fig. 1E) that partial ablation of cholesterol/cholesteryl ester
secretion via the apoB-containing lipoprotein axis (40, 69, 72,
73) was not sufficient by itself to explain the Sar1B:H79G-me-
diated reductions in the levels of transcripts encoding choles-
terol biosynthetic enzymes (Fig. 3B and supplemental Table
S5).
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CHO cells do not have the machinery to produce apoB-con-
taining lipoproteins (74). We therefore used them to explore
further the impact of native and constitutively active Sar1 over-
expression on the levels of mRNAs encoding cholesterol bio-
synthetic enzymes. Sar1A mRNA levels were respectively
increased by 18.68
 2.04- and 22.13
 1.12-fold in the Sar1A
and Sar1A:H79G cell lines; and the corresponding Sar1B values
for the Sar1B and Sar1B:H79G cell lines were 21.17
 2.87 and
38.08
 3.71. Sec and control gene expression was much more
modestly affected (Fig. 4A). In these non-apoB lipoprotein-pro-
ducing cell lines, the overexpression of native Sar1A and Sar1B
reduced cholesterol biosynthesis gene expression, but to a
lesser extent than the control genes (Fig. 4, A and B). By con-
trast, constitutively active Sar1A or Sar1B overexpression
markedly reducedmRNA levels of the cholesterol gene set (Fig.
4B). Hence, these data support the proposition that the reduced
levels ofmost transcripts encoding enzymes for cholesterol bio-
synthesis in the McArdle-RH7777 cell lines expressing Sar1B:
H79G are partially separable from the apoB lipoprotein secre-
tion defect.
The gene expression data from CHO cell line experiments
(Fig. 4B) also suggested that both Sar1 isoforms modulate the
levels of mRNAs encoding cholesterol biosynthetic enzymes.
We examined this further in McArdle-RH7777 cells by deter-
mining the effects of Sar1a and Sar1b knockdown on mRNA
levels of eight representative members of this gene set. All were
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FIGURE 3. Sar1B:H79G decreases cholesterol biosynthesis gene expression in McArdle-RH7777 cells, independently of reduced Apob and Mttp
expression.A,expressionvaluesof 701probe setswere significantly altered (FDR, 0.000215;6.8) bySar1B:H79Gbutnot Sar1A (FDR0.009,1.9) or Sar1B (FDR
0.015,  2.0) overexpression. B, green labeling depicts reduced mRNA levels in stably overexpressing Sar1B:H79G cells. *, expression values are verified by
RT-qPCR. Note: in stably overexpressing Sar1A and Sar1B cells,mRNA levels of these geneswere not reduced (supplemental Table S5).C andD, relative protein
levels of three representative enzymes on the cholesterol biosynthetic pathway (Hmgcs1, Lss, Dhcr7) and a control enzyme, Acsl5, in stably transfected cells
overexpressingSar1B:H79G (C), Sar1A, andSar1B (D).CandDdata (mean
S.E.) are fromat least three independentexperiments. ***,p0.001 versus cellswith
empty vector control; **, p 0.01 versus cells with empty vector control.White line separators indicate that noncontiguous lanes from the samegel are shown.
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decreased (Fig. 4C). Sar1b knockdown generally produced
smaller reductions than knockdown of Sar1a, the predominant
species in McArdle-RH7777 cells. In the double knockdown,
Hmgcs1 and Dhcr7mRNA levels were significantly lower than
in the individual knockdowns (Fig. 4C). However, Hmgcs1 pro-
tein levels were not significantly decreased by either individual
or combined knockdown of Sar1a and Sar1b (Fig. 4D). In com-
parison, Lss protein was significantly reduced by both individ-
ual and combined Sar1a and Sar1b knockdown (Fig. 4E). Com-
bined (not individual) Sar1a and Sar1b knockdown also
produced a nonsignificant rise in Dhcr7 (Fig. 4F, p 0.054 for
difference from scrambled siRNA control). Thus, collectively,
these data indicate that both Sar1A and Sar1B modulate the
levels of mRNAs encoding cholesterol biosynthetic enzymes,
supporting the CHO cell findings (Fig. 4B). Substantiating this
conclusion, we also found that in human liver samples, SAR1A
and SAR1B mRNA levels exhibited no isoform-specific corre-
lations with 20 of the 21 mRNA species encoding cholesterol
biosynthetic enzymes (supplemental Table S6). The only iso-
form-specific correlation was between that of SAR1B and
SC5DL (sterol-C5-desaturase), and both of these genes had
expression values that exhibited positive correlation with
APOB andMTTPmRNA levels (supplemental Table S6).
Next, wewanted to establish whether the reductions in “cho-
lesterol” gene expression (Figs. 3B and 4C) and associated pro-
tein changes (Figs. 3C and 4, D–F) translated into reduced de
novo cholesterol synthesis. As estimated from the incorpora-
tion of [14C]acetate into cholesterol, Sar1B:H79G overexpres-
sionmarkedly reduced the rate of de novo cholesterol synthesis
(Fig. 5A). Additionally, [14C]cholesterol secretion was reduced
(Fig. 5B) but to a lesser extent than de novo cholesterol synthe-
sis. The estimated rate of incorporation of [14C]acetate into
nonesterified fatty acids (NEFA) was also reduced (Fig. 5C), but
this was to a much lesser degree than de novo cholesterol syn-
thesis, and there was no corresponding reduction in 14C-la-
beled NEFA secretion (Fig. 5D). Consistent with comparable
transcription profiles (supplemental Table S5), the Sar1A and
Sar1B cell lines displayed similar rates of de novo cholesterol
synthesis (Fig. 5A), both of whichwere significantly higher than
that of the Sar1B:H79G cell lines.
Individual knockdown of Sar1a and Sar1b did not reduce the
estimated rates of de novo cholesterol synthesis (Fig. 5E). By
contrast, combined Sar1a and Sar1b knockdown had a signifi-
cant impact reducing cellular [14C]cholesterol by 25.33
 8.04%
(Fig. 5E), and this was paired with a small, albeit nonsignificant,
reduction in the estimated rate of [14C]cholesterol secretion
(Fig. 5F). The estimated rate of incorporation of [14C]acetate
into NEFA was also reduced by combined Sar1a and Sar1b
knockdown but by no more than individual Sar1a and Sar1b
knockdowns (Fig. 5,G andH). Thus, these data, combined with
the results in Figs. 3, B–D, and 4, B–F, and previous findings
(52–55), indicate that an insufficiency of Sar1 to support pre-
budding complex assembly or the sequestration of certain
cargo into pre-budding COPII complexes containing constitu-
tively active Sar1 reduce cholesterol biosynthesis.
Because cholesterol synthesismay both affect and be affected
by the processing of Srebp2 in the Golgi apparatus, and COPII
vesicles transport the123-kDa ERmembrane-bound precur-
sor Srepb2 polypeptide to the Golgi (44, 45), we examined the
effects of Sar1B:H79G overexpression and Sar1a and Sar1b
knockdown, on Srepb2 expression. Additionally, we deter-
mined cellular levels of ATF6, a non-sterol-dependent tran-
TABLE 1
Enrichment of gene ontology biological processes terms in the Sar1B:H79G uniquely differentially expressed gene-probe list
The uniquely differentially expressed Sar1B:H79G dataset (see also Fig. 3A) was analysed for enrichment of functionally related Gene Ontology (GO) terms using DAVID
(65, 66).
Cluster description GO terms in cluster
Differentially expressed
genes (n)
Enrichment
score p value range
Regulation of molecular
function and catalytic
activity
0065009; 0050790; 0051336 32 3.70 2.1	 105-
1.5	 103
Cholesterol and lipid
biosynthetic and
metabolic processes
0006695; 0008203; 0016126; 0016125; 0044255; 0006629;
0008610; 0006694; 0008202
32 2.16 7.3	 104-
8.6	 103
Amine catabolic processes 0009310; 0044270; 0009065; 0006527; 0009063; 0009064 9 1.59 3.3	 103-
2.8	 102
Regulation of GTPase
activity
0043087 7 1.54 6.7	 103
Response to nutrient levels
and extracellular stimulus
0031667; 0009991 10 1.49 8.1	 103-
1.0	 102
Regulation of hydrolase
activity
0051336; 0043087; 0032313; 0032483; 0032482; 0032318 13 1.38 1.5	 103-
4.5	 102
Response to glucocorticoid
and corticosteroid
stimulus
0051384; 0031960 5 1.3 3.0	 102-
4.4	 102
Amine catabolic processes 0009310; 0044270; 0042133; 0006575; 0042219; 0042135 16 1.28 3.3	 103-
3.4	 102
Negative regulation of
catalytic activity
0043086; 0033673; 0006469; 0051348 9 1.21 3.4	 103-
3.0	 102
Neurogenesis 0022008; 0048699; 0030182; 0048812; 0048667; 0007409 21 1.18 1.0	 102-
4.0	 102
Response to stress 0006950; 0009605 51 1.04 1.5	 102-
1.7	 102
Response to endogenous
stimulus
0009719 21 0.90 1.2	 102
Protein import into nucleus 0006606; 0051170 7 0.87 2.5	 102-
2.8	 102
Alcohol metabolic process 0006066 23 0.76 3.1	 104
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scription factor. The ATF6 precursor resides in the ER mem-
brane (75) and is activated by the same proteases as Srebp2 in
the Golgi (76, 77) to specifically regulate ER stress-inducible
genes (78).
We found that Sar1B:H79G overexpression led to a small,
but nonsignificant, rise in the level of precursor Srebp2 (Fig. 6A)
and a significant increase in the level of the 68-kDa processed
polypeptide (Fig. 6,B andC). Levels of the control proteinATF6
were not altered (supplemental Fig. S3). Thus, these results
indicate that there was sufficient endogenous Sar1 in the Sar1B:
H79G cell lines (Fig. 2C) to support the ER export of both
Srebp2 and ATF6 precursors.
Sar1a knockdown did not reduce either Srebp2 protein
levels (Fig. 6, D–F) or Scap and Srebp2 mRNA expression
(supplemental Table S7). Likewise, combined Sar1a and Sar1b
knockdown did not decrease Srebp2 protein levels or its pro-
cessing (Fig. 6,D–F). By contrast, knockdown of Sar1b (minor-
ity Sar1 species in McArdle-RH7777 cells), which had no
impact on de novo cholesterol synthesis (Fig. 5E), significantly
reduced (by 13.2 
 1.93% versus scrambled, p  0.002 for dif-
ference) the level of processed Srebp2 (Fig. 6, G–I) and Scap
mRNA (supplemental Table S7). In the control analysis, Sar1b
knockdown did not reduce the amount of the non-sterol-re-
sponsive transcription factor ATF6 (supplemental Fig. S3).
DISCUSSION
This study was designed to examine the interplay between
apoB-containing lipoprotein secretion and de novo cholesterol
synthesis and their reliance on the common and individual
activities of the two Sar1 isoforms.We provide strong evidence
that Sar1B promotes the secretion of triglyceride-rich, apoB-
containing lipoproteins from the liver, which would neatly
explain the counter-intuitive observation that some CMRD
children develop hepatic steatosis, despite severe intestinal fat
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malabsorption (16–18). Moreover, we show that Sar1A antag-
onizes Sar1B’s lipoprotein secretion-promoting activity. We
also establish that SAR1B is the predominantly expressed iso-
form in human jejunum and liver, two organs that substantially
contribute to circulating levels of cholesterol (12, 79, 80), and
that Sar1 deficiency, as well as constitutively active Sar1,
decrease the levels of transcripts encoding cholesterol biosyn-
thetic enzymes and de novo cholesterol synthesis. The results,
which help explain the unique nature of the very severe hypo-
cholesterolemia phenotype (i.e. reduced levels of all cholesterol-
0.0
0.5
1.0
1.5
C
ho
le
st
er
ol
 S
yn
th
es
is
nm
ol
/h
r/m
g 
pr
ot
ei
n
A
0.00
0.05
0.10
0.15
0.20
***
*
*
C
ho
le
st
er
ol
 S
ec
re
tio
n
nm
ol
/h
r/m
g 
pr
ot
ei
n
B
C
0.00
0.02
0.04
0.06
0.08
0.10
D
0.00
0.25
0.50
0.75
1.00
1.25
E
0.00
0.05
0.10
0.15
0.20
F
0.00
0.02
0.04
0.06
0.08
G
p=0.2706 p=0.2670 *
p=0.0474 *
p=0.0239
H
N
EF
A
 S
ec
re
tio
n
nm
ol
/h
r/m
g 
pr
ot
ei
n
N
EF
A
 S
yn
th
es
is
nm
ol
/h
r/m
g 
pr
ot
ei
n
0.00
0.02
0.04
0.06
0.08
0.10
*
C
ho
le
st
er
ol
 S
yn
th
es
is
nm
ol
/h
r/m
g 
pr
ot
ei
n
C
ho
le
st
er
ol
 S
ec
re
tio
n
nm
ol
/h
r/m
g 
pr
ot
ei
n
0.00
0.02
0.04
0.06
0.08
N
EF
A
 S
ec
re
tio
n
nm
ol
/h
r/m
g 
pr
ot
ei
n
N
EF
A
 S
yn
th
es
is
nm
ol
/h
r/m
g 
pr
ot
ei
n
p=0.1805 *
*
*** ***
*
****
Control Sar1A Sar1B Sar1B:
H79G
Control Sar1A Sar1B Sar1B:
H79G
Control Sar1A Sar1B Sar1B:
H79G
Control Sar1A Sar1B Sar1B:
H79G
Scr Sar1a Sar1b Sar1a
&
Sar1b
Scr Sar1a Sar1b Sar1a
&
Sar1b
Scr Sar1a Sar1b Sar1a
&
Sar1b
Scr Sar1a Sar1b Sar1a
&
Sar1b
p=0.0170
p=0.0129
p=0.0003 p=0.0008
p=0.0240
p=0.0269
p=0.0004
p=0.0285 p=0.0544
p=0.0124
p=0.2069
p=0.0707
FIGURE 5. Sar1B:H79G and combined Sar1a and Sar1b deficiency reduce de novo cholesterol synthesis to greater extents than cholesterol secretion.
A–H,McArdle-RH7777 cells stably overexpressing specified recombinant Sar1 protein or control McArdle-RH7777 cells transfected with specified siRNA were
labeledwith 2mM [14C]acetate for 5 h. A and B, [14C]cholesterol in the cell (A) andmedia (B) of specified cell lines. C andD, [14C]NEFA contents in the cell (C) and
media (D) of specified cell lines. E and F, [14C]cholesterol contents in the cell (E) andmedia (F) ofMcArdle-RH7777 cells transfectedwith specified siRNAs.G and
H, [14C]NEFA contents in the cell (G) andmedia (H) of cells transfectedwith specified siRNAs. Data (mean
 S.E.) are from three (A–D) or four (E–H) independent
experiments, Scr, scrambled siRNA. A and B, ***, p 0.001 versus cells with empty vector control; ****, p 0.0001 versus cells with empty vector control; *, p
0.05 versus cells expressing Sar1B:H79G. C, *, p 0.05 versus cells with empty vector control. E and H, *, p 0.5 versus scrambled control siRNA.
Sar1B-mediated Regulation of Triglyceride and Cholesterol
4254 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 7•FEBRUARY 14, 2014
 at RA
D
BO
U
D
 U
N
IV
ERSITEIT N
IJM
EG
EN
 on M
arch 6, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
carrying lipoproteins) that features in CMRD (16, 18, 81), indi-
cate that Sar1B makes a substantial contribution to the
regulatory processes controlling ER and blood cholesterol
levels.
As touched upon in the Introduction, there is a close spatial
and temporal association between apoB and the ERmembrane,
extending from its point of entry to its co-translational assem-
bly into a nascent lipoprotein (82). This transformation is pro-
moted by triglyceride and cholesterol synthesis (72, 82–88),
plus the conversion of membrane-bound cholesterol to choles-
teryl esters (40, 69, 73, 83, 89), whereas the transport of newly
assembled apoB lipoproteins from their sites of synthesis in the
ER to the Golgi apparatus is mediated by the COPII transport
machinery.
With the results from this study, we can now conclude that
only Sar1B, and not Sar1A, can secure the efficient secretion of
nascent, triglyceride-rich, apoB-containing lipoproteins and
that it does so whether they are assembled around apoB48 or
apoB100 and in the liver or intestine. Indeed, we found that
Sar1A antagonizes Sar1B’s apoB lipoprotein secretion-promot-
ing activity, and this antagonism was more pronounced for
larger andmore lipid-laden apoB lipoproteins. Thus, these data
suggest that Sar1B may have a unique capacity to promote the
production of COPII vesicles of the size required to secure the
ER export of triglyceride-rich, apoB-containing lipoproteins.
This proposition fits well with existing knowledge. First, a few
abnormally small chylomicrons (diameter 63 
 19 nm) have
been found within the abluminal space of CMRD patients’
enterocytes (90), implying that chylomicrons (which are assem-
bled around apoB48) exit the ER in standard sized COPII vesi-
cles so long as they remain small. Second, in both of the two
unrelated CMRD patients investigated, VLDL (which is assem-
bled around apoB100) was markedly reduced (91). Third, in rat
hepatocytes, VLDL formed around either apoB48 or apoB100
buds from the ER in larger sized COPII vesicles than do protein
cargo (92). Moreover, a significant proportion of the apoB100
lipoproteins are found in larger sized COPII vesicles than
apoB48 particles (92), likely reflecting that apoB100 has more
neutral lipid-binding motifs than apoB48. Indeed, assembling
apoB100 lipoproteins not only require more lipid than apoB48
to attain a soluble conformation, they will, with all other things
being equal (e.g. lipid availability), bind considerably more lipid
than apoB48 (12, 93, 94).
Although early investigations on CMRD patient samples
revealed that both intestinal and hepatic apoB-containing lipo-
proteins were produced in this condition (81, 90), a re-appraisal
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of these data is long overdue given the new information on Sar1
(53–55) and the results reported herein. Thus, the totality of the
data indicates that the removal of apoB lipoproteins from their
sites of synthesis in the ER lumen may facilitate the apoB lipo-
protein assembly process itself. We note, for example, that
Sar1B’s lipoprotein secretion-promoting activity was associ-
ated with a marked increase in ApoB expression (Fig. 2D) but
not of genes regulating triglyceride synthesis (supplemental
Table S5) and that Sar1B promoted the production of increased
numbers of apoB lipoproteins rather than of more lipid-laden
ones (Fig. 1, C and D). In comparison, Sar1B mutations in
CMRD culminate in the production of abnormally large chylo-
microns (90) and a lipid phenotype resembling that observed in
the recessively inherited lipoprotein production disorder,
abetalipoproteinemia; specifically, enterocytes from CMRD
patients contain large cytosolic lipid droplets, even in the fast-
ing state (90). Thus, loss of Sar1B’s lipoprotein secretion-pro-
moting activity appears to impair apoB lipoprotein production,
albeit to a lesser extent than the impairment that occurs in
abetalipoproteinemia.
Tantalizing clues as to how Sar1B could promote the assem-
bly of specialist pre-budding complexes for mediating the
onward transport of nascent apoB lipoproteins have emerged
from two in vitro studies (56, 95). The first showed that Sar1B
relaxes its hostmembrane to a greater extent that Sar1A, imply-
ing the former may promote assembly of large radius pre-bud-
ding complexes more readily than the latter, all other factors
being equal (95). The second, incidentally foundduring study of
the pathogenic Sec23A-F382L mutation (56), is that Sar1B-
Sec23-Sec24 pre-budding complexes have lower affinity for
Sec13/Sec31A than equivalent Sar1A-Sec23-Sec24 complexes,
reducing Sec23-mediated hydrolysis of GTP on Sar1. The
implication, which seems entirely consistent with their study’s
morphological analyses, is that Sar1B serves to delay, relative to
Sar1A, COPII coat disassembly, thereby tilting the balance
toward continuedCOPII vesicle expansion. In fact, a prolonged
COPII vesicle assembly process could permit elongating apoB
polypeptides to commandeer its ER-to-Golgi transport vesicle
early on in the lipoprotein productionprocess (10–15min for
apoB100 (13)), well before it undergoes the huge increase in size
that occurs during transformation of hepatic and intestinal
apoB into lipoproteins.
We found that relative to SAR1A, SAR1B mRNA levels are
much higher in the upper gastrointestinal mucosa than in liver.
Nonetheless, it is apparent that SAR1B contributes in a major
way to hepatic lipid metabolism given the combination of our
apoB lipoprotein studies (e.g. Figs. 1B and 2,D and E), the find-
ing of hepatic steatosis in some children with CMRD (16, 17,
91), the highly significant positive correlations between SAR1B,
APOB, andMTTPmRNA in human liver samples, and the find-
ing that partial Sar1b knockdown reduced Srebp2 processing
(Fig. 6H) paired with the expected corresponding reduction in
levels of mRNAs encoding enzymes active in cholesterol bio-
synthesis (Fig. 4C).
We found that Sar1 had no isoform-specific effects on the
expression of genes regulating triglyceride or fatty acid metab-
olism (supplemental Table S5). Moreover, even though consti-
tutively active Sar1B blocked apoB lipoprotein secretion (Fig.
1A), it did not reduce the expression of most members of these
two gene sets, suggesting that the intracellular transport of
Srebp1, the best characterized transcription factor regulating
fatty acid and triglyceride gene expression (47, 96–99), was
maintained in our Sar1B:H79G cell lines. Indeed, because our
stable cell lines overexpressing Sar1B:H79G induced a compen-
satory rise of endogenous Sar1A (Fig. 2C), we very likely created
the means for allowing the onward transport of some ER cargo,
while facilitating detection of Sar1B-specific phenotypes.
Although we found that native Sar1A and Sar1B overexpres-
sion had no, orminimal, effect on the levels of mRNA encoding
cholesterol biosynthetic enzymes (supplemental Table S5 and
Fig. 4B), they did reduce de novo cholesterol biosynthesis, albeit
to a much lesser extent than Sar1B:H79G overexpression. It
seems particularly pertinent that Sar1A overexpression, which
markedly decreased apoB lipoprotein secretion (Fig. 1E), was
associated with increased Hmgcs1 protein levels, and Sar1B
overexpression was associated with reduced Lss protein. Con-
ceivably, this counter-intuitive rise in Hmgcs1 protein (but not
mRNA) could reflect a response to the diversion of acetyl-CoA
(Fig. 3B) away from the cholesterol biosynthesis pathway
toward an alternative metabolic pathway(s), for example, path-
ways promoting the acetylation of ER resident and ER-transit-
ing proteins (100) and/or histone tails (101). In comparison, the
reduction in Lss protein associated with Sar1B overexpression,
however it is mediated, may reflect part of an adaptive response
that serves to reduce flux through the cholesterol biosynthetic
pathway.
The observation that Sar1B:H79G overexpression reduced
the levels of most transcripts encoding cholesterol biosynthetic
enzymes (Fig. 3B and supplemental Table S5) and that this
reduction was paired with increased, rather than decreased,
Dhcr7 protein levels is of interest (Fig. 3C). Dhcr7 deficiency in
embryonic mouse brains leads to a compensatory rise in
Hmgcs1 protein (102). This reciprocal relationship also devel-
ops on Sar1B:H79G overexpression, despite it having compara-
ble effects on Hmgcs1 and Dhcr7 mRNA levels (supplemental
Table S5). Likewise, the expected reciprocal relationship
between reduced de novo cholesterol synthesis and increased
Srepb2processing (Fig. 6,B andC) was sustained.However, this
increased processing was insufficient to secure the expected
corresponding increases in cholesterol biosynthetic gene
expression, as judged by mRNA measurements.
There are several possible explanations that could account
for the effect of the Sar1B:H79G mutation on the levels of
mRNA encoding cholesterol metabolism genes. For instance, it
could reflect reduced Srebp2-mediated activation of these
genes, for example, as a result of dimerization of Srebp2 with
Srebp1c and/or another transcriptional co-factor (103, 104).
Next, the processes regulating stabilization of one or more of
these transcripts may be compromised (105). Alternatively, it
could reflect their enhanced degradation, for example, via an
miRNA-mediated (106) or IRE1-mediated (107) mecha-
nism(s).What is clear is that the incorporation of constitutively
active Sar1B into pre-budding complexes would sequester cer-
tain ER cargo as a result of delaying the completion of COPII
vesicle assembly and thus the fission of COPII vesicles, along
with their selected cargo, from the ER membrane (51, 52, 55).
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Furthermore, reducing cholesterol secretion via the apoB lipo-
protein pathway does not adequately explain the reduced
mRNA levels associatedwith expression of constitutively active
Sar1 (e.g. supplemental Fig. S2).
We also found that reducing the level of Sar1a protein
decreased the levels of mRNA encoding cholesterol biosyn-
thetic enzymes (Fig. 4C), but despite this, estimated rates of de
novo cholesterol synthesis and secretion were not reduced.
Consistent with this, Srebp2 processing was not increased.
Thus, our results indicate that in our cell system there was
sufficient Sar1 (i.e. residual Sar1a protein and Sar1b) to initiate
the assembly of pre-budding COPII complexes for ER export of
Srebp2 and that factors other than reduced Srebp2 processing
underlie the reduced mRNA levels of the cholesterol gene set.
By contrast, the reduced processing of Srebp2 associated with
knockdown of Sar1b (minority species) may explain some of
the reduction in the levels of mRNA encoding cholesterol
biosynthetic enzymes. Hence, the observed cholesterol/
Srebp2/mRNA differences between the Sar1B:H79G overex-
pressing cells and cells deficient for Sar1a or Sar1b indicate that
the processes regulating de novo cholesterol synthesis in apoB
lipoprotein-producing cells may be somewhat more complex
than in other cell types. Furthermore, modulation of Sar1A and
Sar1B levels in such cells affects processes regulating the acces-
sibility of de novo synthesized cholesterol within the ER mem-
brane (108, 109), its subsequent transfer to andutilization in the
plasma membrane (110, 111), in addition to its use in the pro-
duction of apoB- and apoA1-containing lipoproteins (38–40,
112).
The observation that Sar1 knockdown reduced de novo cho-
lesterol synthesis by 25% is likely to be clinically relevant,
especially given that this phenotype developed in cells that
retained30% of their total Sar1 (i.e. a and b) protein. It is also
very striking that the severe hypocholesterolemia of CMRDdif-
fers from abetalipoproteinemia (1, 113) and familial hypobeta-
lipoproteinemia (14) in that it is characterized by very low levels
of high density lipoprotein (HDL) cholesterol, and indeed, in
some cases, absence of this so-called good cholesterol-carrying
lipoprotein particle (16, 18, 81, 114). HDL is formed through
the efflux of plasma membrane cholesterol onto lipid-free
apoAI, and cellular cholesterol levels are a major determinant
of this efflux from the plasmamembrane (114, 115). Therefore,
it must be acknowledged that SAR1Bmutations in CMRD very
likely contribute to the low HDL cholesterol phenotype
through an overall reduction inwhole-body de novo cholesterol
synthesis and that this reduction may, to a large extent, stem
from those cells that have relatively low Sar1A levels or a high
requirement for de novo synthesized cholesterol, or a combina-
tion of both.
With respect to understanding the role of hepatic de novo
cholesterol synthesis in regulating apoB-containing lipoprotein
secretion, in vivo data are rather sparse. One study found that
liver-specific knockdownofHMGCR in 3- and 4-week-oldmice
significantly reduced plasma apoB, plus total and LDL choles-
terol levels (116). Conversely, another showed that hepatic
overexpression of Fdft1, which produces the first specific inter-
mediate in the cholesterol biosynthetic pathway (Fig. 3B),
increased de novo cholesterol synthesis and the production of
cholesterol-enriched VLDL, culminating in markedly raised
plasma levels of total and LDL cholesterol (87). Because the
post-squalene cholesterol reactions (Fig. 3B) occur on the ER
membrane (24–28), it is plausible that reduced de novo choles-
terol synthesis may decrease ACAT activity. Indeed, Parini et
al. (38) have shown that culturing cells in cholesterol-enriched
media increases the enzymatic activity of ACAT2, the major
cholesterol-esterifying enzyme in hepatocytes (39), and Temel
et al. (40) demonstrated that ACAT2 stimulates cholesteryl
ester secretion in apoB lipoproteins. Furthermore, it has been
demonstrated that MTTP increases ACAT’s activity by trans-
ferring its reaction products (i.e. cholesteryl esters) onto assem-
bling apoB lipoproteins, thereby removing product inhibition
(69). Thus, in light of these considerations, and the data pre-
sented here, it seems to make sense that in CMRD, VLDL, and
LDL in the patients contain, as percentage of total cholesterol,
significantly less cholesteryl ester than control samples (81),
whereas their VLDL carries a larger than usual triglyceride load
(16, 81, 90). More fundamentally, the cholesterol/cholesteryl
ester and apoB/MTTP pathways work with each other, as well
as the COPII and Srepb2/Scap machineries, to maintain the
cholesterol content of the ER membrane at a concentration(s)
compatible with this cellular compartment’s biosynthetic orga-
nizing functions (117).
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